712 related articles for article (PubMed ID: 34068143)
1. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
2. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
[TBL] [Abstract][Full Text] [Related]
3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
4. Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
Sun D; Liu J; Zhou H; Shi M; Sun J; Zhao S; Chen G; Zhang Y; Zhou T; Ma Y; Zhao Y; Fang W; Zhao H; Huang Y; Yang Y; Zhang L
J Thorac Oncol; 2023 Jul; 18(7):869-881. PubMed ID: 36948245
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumours and their microenvironment.
de Hosson LD; Takkenkamp TJ; Kats-Ugurlu G; Bouma G; Bulthuis M; de Vries EGE; van Faassen M; Kema IP; Walenkamp AME
Cancer Immunol Immunother; 2020 Aug; 69(8):1449-1459. PubMed ID: 32270230
[TBL] [Abstract][Full Text] [Related]
9. Expression of the immune checkpoint VISTA in breast cancer.
Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
[TBL] [Abstract][Full Text] [Related]
10. The levels of immunosuppressive checkpoint protein PD-L1 and tumor-infiltrating lymphocytes were integrated to reveal the glioma tumor microenvironment.
Zhang W; Liu L; Liu X; Han C; Li Q
Environ Toxicol; 2024 Feb; 39(2):815-829. PubMed ID: 37792606
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in sebaceous carcinomas.
Saliba M; Shaheen M; Hajj RE; Abbas F; Bashir S; Sheikh UN; Mahfouz R; Loya A; Khalifeh I
Cancer Immunol Immunother; 2021 Jul; 70(7):1907-1915. PubMed ID: 33398391
[TBL] [Abstract][Full Text] [Related]
12. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Hudson K; Cross N; Jordan-Mahy N; Leyland R
Front Immunol; 2020; 11():568931. PubMed ID: 33193345
[TBL] [Abstract][Full Text] [Related]
13. IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration.
Yang W; Chen Z; Qu L; Zhang C; Chen H; Zheng J; Chen W; Tan X; Shi C
Curr Cancer Drug Targets; 2024; 24(6):642-653. PubMed ID: 38310462
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Dislich B; Stein A; Seiler CA; Kröll D; Berezowska S; Zlobec I; Galvan J; Slotta-Huspenina J; Walch A; Langer R
Cancer Immunol Immunother; 2017 Jun; 66(6):777-786. PubMed ID: 28289861
[TBL] [Abstract][Full Text] [Related]
15. A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
[TBL] [Abstract][Full Text] [Related]
16. Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells.
Lazarus J; Oneka MD; Barua S; Maj T; Lanfranca MP; Delrosario L; Sun L; Smith JJ; D'Angelica MI; Shia J; Fang JM; Shi J; Di Magliano MP; Zou W; Rao A; Frankel TL
Ann Surg Oncol; 2019 Sep; 26(9):2821-2830. PubMed ID: 31250346
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
[TBL] [Abstract][Full Text] [Related]
18. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
Ho M; Bonavida B
Cells; 2024 May; 13(10):. PubMed ID: 38786085
[TBL] [Abstract][Full Text] [Related]
19. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K; Zygoura P; Norkin M; Tissot S; Shakarishvili N; Popat S; Curioni-Fontecedro A; O'Brien M; Pope A; Shah R; Fisher P; Spicer J; Roy A; Gilligan D; Rusakiewicz S; Fortis E; Marti N; Kammler R; Finn SP; Coukos G; Dafni U; Peters S; Stahel RA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880184
[TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Baba Y; Nomoto D; Okadome K; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Baba H
Cancer Sci; 2020 Sep; 111(9):3132-3141. PubMed ID: 32579769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
